不可逆电穿孔使初始不可切除的局部进展期胰腺腺癌获得手术机会:IRECAP II期研究
IRECAP为II期单中心开放标签前瞻性非随机试验,局部进展期胰腺癌患者先接受3个月新辅助化疗,稳定者行CT引导经皮不可逆电穿孔,最终35%(6/17)获得R0或R1切除,R0/R1切除者中位总生存31个月,未切除或R2切除者21个月(logrank P=0.044)。
要点
- 局部进展期胰腺癌经3个月新辅助化疗稳定后行CT引导经皮不可逆电穿孔,R0/R1切除率为35%(6/17)。
- 不可逆电穿孔相关严重不良事件发生率为58%(10/17,共25例次),无治疗相关死亡。
- R0/R1切除者中位总生存31个月,未切除或R2切除者21个月(logrank P=0.044)。
核心结论
- 新辅助化疗后行不可逆电穿孔可使35%的局部进展期胰腺癌获得R0或R1切除,似乎与更高的总生存相关。
研究设计与样本
- II期、单中心、开放标签、前瞻性、非随机试验(NCT03105921);纳入17例局部进展期胰腺癌患者(男6例、女11例,中位年龄61岁,范围37-77岁),先接受3个月新辅助化疗,稳定者行CT引导经皮不可逆电穿孔,计划于IRE后28至90天手术,以手术标本切缘(R0/R1/R2)为参考标准。
诊断标准与关键数值
- 以手术标本切缘评估R0/R1/R2;R1-R0率为35%(6/17);不可逆电穿孔操作成功率100%;10/17(58%)发生25例次IRE相关严重不良事件。
临床应用与阅片要点
- 不可逆电穿孔后至手术间有4例进展而未手术;13例最终手术者中6例因胰腺切除被排除、3例弥漫性腹膜癌、2例大血管包裹、1例术前未诊断的肝细胞癌。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The aim of the IRECAP study was to evaluate the rate of locally advanced pancreas cancer patients (LAPC) who could undergo R0 or R1 surgery after irreversible electroporation (IRE).
MATERIALS AND METHODS: IRECAP study is a phase II, single-center, open-label, prospective, non-randomized trial registered at clinicaltrials.gov (NCT03105921). Patients with LAPC were first treated by 3-month neo-adjuvant chemotherapy in order to avoid inclusion of either patients with LAPC having become resectable after chemotherapy or patients with rapid disease progression. In cases of stable disease, IRE was performed percutaneously under CT guidance. Surgery was planned between 28 and 90 days after IRE. Tumor specimens were studied to evaluate the resection margins (R0/R1/R2).
RESULTS: Six men and 11 women were included (median age 61 years, range 37-77 years). No IRE-related death was observed. Ten patients (58%, 10/17) experienced 25 serious adverse events related to IRE. Four patients progressed between IRE and surgery and were excluded from surgery. Thirteen patients were finally operated, six withheld for pancreas resection, three for diffuse peritoneal carcinosis, two for massive vascular entrapment, and one for hepato-cellular carcinoma not diagnosed before surgery. Rate of R1-R0 was 35% (n = 6/17). Median overall survival was 31 months (95% CI; 4-undefined) for the six patients with R0/R1 resection and 21 months (95% CI; 4-25) for the 11 patients without resection or R2 resection (logrank p = 0.044).
CONCLUSION: After neoadjuvant chemotherapy, IRE could provide R0 or R1 resection in 35% of LAPC, which seems to be associated with higher OS.
CLINICAL RELEVANCE STATEMENT: After induction chemotherapy, stable locally advanced pancreatic cancers can be treated by irreversible electroporation, which could lead to a secondary 35% rate of R0 or R1 surgical resection which may be associated with a significantly higher overall survival.
KEY POINTS: • In cases of unresectable LAPC (locally advanced pancreatic cancer), percutaneous irreversible electroporation (pIRE) is feasible (100% success rate of the procedure), but is associated with a 58% rate of grade 3-4 adverse events. • In patients with unresectable LAPC, pIRE could lead 35% of patients to R0-R1 surgical resection. • From IRE, median overall survival was 31 months (95% CI; 4-undefined) for the patients with R0/R1 resection and 21 months (95% CI; 4-25) for the patients without resection or R2 resection (logrank p = 0.044).
引用
- Tasu JP, Herpe G, Damion J, et al. Irreversible electroporation to bring initially unresectable locally advanced pancreatic adenocarcinoma to surgery: the IRECAP phase II study. Eur Radiol. 2024. PMID: 38494526. doi:10.1007/s00330-024-10613-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。